ArticleIntegrative biology : quantitative biosciences from nano to macro2013
Clinically-translated silica nanoparticles as dual-modality cancer-targeted probes for image-guided surgery and interventions.
Article in Integrative biology : quantitative biosciences from nano to macro, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 176 citations in OpenAlex.
- Use of Ultrasmall Core-Shell Fluorescent Silica Nanoparticles for Image-Guided Sentinel Lymph Node Biopsy in Head and Neck Melanoma: A Nonrandomized Clinical Trial.JAMA network open · 2021Trial
- Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe.Science translational medicine · 2014Trial
- Intravital microscopy for nanomedicine: investigating nanoparticle-tissue interactions in the native state.RSC advances · 2026Review
- Multiscale characterization of ultrasmall fluorescent core-shell silica nanoparticles in cartilage and synovial joints reveals rapid cartilage penetration and sustained joint residence.Acta biomaterialia · 2025Article
- Progress in Nanotechnology for Treating Ocular Surface Chemical Injuries: Reflecting on Advances in Ophthalmology.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Current and Developing Lymphatic Imaging Approaches for Elucidation of Functional Mechanisms and Disease Progression.Molecular imaging and biology · 2024Review
- Comparative aspects of targeted sentinel lymph node mapping in veterinary and human medicine: opportunities for future research.Frontiers in medicine · 2024Review
- New Opportunities and Old Challenges in the Clinical translation of Nanotheranostics.Nature reviews. Materials · 2023Article
- Magnetoresponsive fluorescent core-shell nanoclusters for biomedical applications.Nanoscale advances · 2023Article
- Medical Imaging Technology and Imaging Agents.Advances in experimental medicine and biology · 2023Article
- Low frequency vibrating magnetic field-triggered magnetic microspheres with a nanoflagellum-like surface for cancer therapy.Journal of nanobiotechnology · 2022Article
- Advanced Optical Imaging-Guided Nanotheranostics towards Personalized Cancer Drug Delivery.Nanomaterials (Basel, Switzerland) · 2022Review
- Polyglutamate-based nanoconjugates for image-guided surgery and post-operative melanoma metastases prevention.Theranostics · 2022Article
- Cancer nanotechnology: current status and perspectives.Nano convergence · 2021Review
- Physiological and Pathological Factors Affecting Drug Delivery to the Brain by Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Fluorescent Silica Nanoparticles to Label Metastatic Tumor Cells in Mineralized Bone Microenvironments.Small (Weinheim an der Bergstrasse, Germany) · 2021Article
- Article
- Co-adsorption of synthetic Mincle agonists and antigen to silica nanoparticles for enhanced vaccine activity: A formulation approach to co-delivery.International journal of pharmaceutics · 2021Article
- Hyperfluorescence Imaging of Kidney Cancer Enabled by Renal Secretion Pathway Dependent Efflux Transport.Angewandte Chemie (International ed. in English) · 2021Article
- Recent Progress in Nanomedicine for Melanoma Theranostics With Emphasis on Combination Therapy.Frontiers in bioengineering and biotechnology · 2021Review
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Early diagnosis and treatment of melanoma are essential to minimizing morbidity and mortality. The presence of lymph node metastases is a vital prognostic predictor, and accurate identification by imaging has important implications for disease staging, prognosis, and clinical outcome. Sentinel lymph node (SLN) mapping procedures are limited by a lack of intraoperative visualization tools that can aid accurate determination of disease spread and delineate nodes from adjacent critical neural and vascular structures. Newer methods for circumventing these issues can exploit a variety of imaging tools, including biocompatible particle-based platforms coupled with portable device technologies for use with image-guided surgical and interventional procedures. We describe herein a clinically-translated, integrin-targeting platform for use with both PET and optical imaging that meets a number of key design criteria for improving SLN tissue localization and retention, target-to-background ratios, and clearance from the site of injection and the body. The use of such agents for selectively probing critical cancer targets may elucidate important insights into cellular and molecular processes that govern metastatic disease spread. Coupled with portable, real-time optical camera systems, we show that pre-operative PET imaging findings for mapping metastatic disease in clinically-relevant larger-animal models can be readily translated into the intraoperative setting for direct visualization of the draining tumor lymphatics and fluorescent SLN/s with histologic correlation. The specificity of this platform, relative to the standard-of-care radiotracer, (18)F-FDG, for potentially discriminating metastatic disease from inflammatory processes is also discussed in the setting of surgically-based or interventionally-driven therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.